Chronic back pain affects millions worldwide, yet treatments typically address symptoms rather than underlying cellular damage. This breakthrough reveals how targeting aging cells in spinal discs could prevent degeneration before it becomes irreversible, potentially transforming orthopedic medicine from reactive to preventive care.
Researchers demonstrated that combining dasatinib (a cancer drug) with quercetin (a plant flavonoid) significantly delayed disc degeneration in genetically susceptible mice. The senolytic cocktail reduced key aging markers including p19ARF, p21, and inflammatory secretory proteins while improving disc cell survival and preventing nucleus pulposus fibrosis. Transcriptomic analysis identified JNK signaling pathway modulation as a primary mechanism, with specific genes Junb and Zfp36l1 emerging as therapeutic targets. Human cell studies confirmed these benefits translate across species.
This work validates senescent cell removal as a viable strategy for spinal health, joining growing evidence that senolytics could address multiple age-related conditions simultaneously. Unlike previous attempts with navitoclax, the dasatinib-quercetin combination proved effective against both genetic and aging-related disc deterioration. The identification of shared molecular pathways between mouse models and human cells strengthens clinical translation prospects. However, the genetic predisposition model may not fully represent typical human disc disease progression. While dasatinib requires prescription access, quercetin's availability as a supplement makes this combination particularly intriguing for preventive applications. This represents confirmatory evidence supporting senolytics' broader therapeutic potential, though human trials remain essential for validating safety and efficacy in clinical populations.
